ClinicalTrials.gg

Program

becotatug

Also written as “JMT101”, “JMT101 Injection” and “JMT101 injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Nasopharyngeal Neoplasms, led by CSPC Pharmaceutical Group.

Furthest: phase 3, since Mar 13, 202411 company-led studies, 8 open or runningNext primary completion: Mar 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group118 open or runningphase 3since Mar 13, 2024Jun 16, 2020Mar 26, 2027phase 3 · NCT06380348
  • Named in CSPC Pharmaceutical Group’s own pipeline as JMT101, phase 3, as of Aug 20, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2020First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04448379 · 48 enrolled · China
  2. Dec 23, 2020Phase 1 study in Advanced Solid TumorNCT04689100 · 259 enrolled · China
  3. Nov 1, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05132777 · 155 enrolled
  4. Oct 13, 2023Phase 2 study in Colorectal NeoplasmsNCT06089330 · 102 planned
  5. Mar 13, 2024Phase 3 study in Squamous Cell Non-small Cell Lung CancerNCT06319313 · 534 planned
  6. Apr 9, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06380348 · 398 planned
  7. Apr 26, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06391944 · 161 enrolled · China
  8. Dec 7, 2024Phase 3 study in Locally Advanced or Metastatic Non-squamous NSCLCNCT06735391 · 516 planned · China
  9. Mar 21, 2025Phase 2 study in RecurrenceNCT06892431 · 150 planned
  10. Apr 25, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06989671 · 430 planned
  11. Aug 14, 2025Phase 3 study in Colorectal NeoplasmsNCT07134205 · 252 planned

Ahead

  1. Mar 26, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06380348
  2. Jun 1, 2027Primary completion: phase 3 study in Colorectal NeoplasmsNCT07134205
  3. Dec 30, 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06989671

TargetBeta

“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, becotatug targets, binds to and prevents the activation of EGFR. This inhibits EGFR-mediated signaling and proliferatio…”NCIt, read by Claude
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor (EGFR), ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07134205Colorectal Neoplasms3Not yet recruitingJun 1, 2027252
NCT06989671Squamous Cell Carcinoma of Head and Neck2Not yet recruitingDec 30, 2027430
NCT06892431Recurrence2Not yet recruitingDec 31, 2025150
NCT06735391Locally Advanced or Metastatic Non-squamous NSCLC · China3RecruitingSep 30, 2026516
NCT06391944Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingMay 17, 2023161
NCT06380348Carcinoma, Non-Small-Cell Lung3Not yet recruitingMar 26, 2027398
NCT06319313Squamous Cell Non-small Cell Lung Cancer3Not yet recruitingJul 1, 2026534
NCT06089330Colorectal Neoplasms2Not yet recruitingJul 2024102
NCT05132777Carcinoma, Non-Small-Cell Lung2UNKNOWNSep 30, 2023155
NCT04689100Advanced Solid Tumor · China1UNKNOWNDec 31, 2021259
NCT04448379Carcinoma, Non-Small-Cell Lung · China1UNKNOWNDec 31, 202148

How it is read

Names in the registry

  • “JMT101”, 9 entries
  • “JMT101 Injection”, 2 entries
  • “JMT101 injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.